GlassScriptPhysician profile
Stephen Thomas Mccarthy
NPI 1912308743
$6,228.04
in general payments reported to CMS, 2019-2025
17 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,575 · 2023: $304 · 2024: $999 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.07 |
| Education | $123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,849.07 | 2021-2024 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $827.72 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $681.51 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $680.94 | 2021-2025 | Invega Sustenna |
| Abbvie INC. | $532.24 | 2021 | |
| Vanda Pharmaceuticals INC. | $477.65 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $290.21 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $263.68 | 2021 | |
| Neos Therapeutics, LP | $180.62 | 2021 | |
| Ironshore Pharmaceuticals INC. | $124.18 | 2021 | |
| Sunovion Pharmaceuticals INC. | $97.41 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.93 | 2021 | |
| Orexo US, INC. | $47.29 | 2021 | |
| Lundbeck LLC | $39.54 | 2021 | |
| Allergan, INC. | $20.86 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $16.97 | 2024 | Brixadi |
| Neurocrine Biosciences, INC. | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.